Bryan O Irving

US Patent:

20090293137, Nov 26, 2009

Filed:

Nov 16, 2006

Appl. No.:

11/814413

Inventors:

Katherin E. Combs - Spring TX, US
Frederic J. de Sauvage - Foster City CA, US
Liangfen Fan - Spring TX, US
Ellen Filvaroff - San Francisco CA, US
Allison A. B. Horner - Dickinson TX, US
Bryan Irving - San Francisco CA, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca McLain - San Antonio TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Philips - Palo Alto CA, US
Carolina Rangel - Houston TX, US
Tracy E. W. Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Teresa G. Townsend - Houston TX, US
Peter Vogel - The Woodlands TX, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01K 67/027
C12N 5/06
C07K 16/18
C12Q 1/02
A61K 39/395

US Classification:

800 3, 435325, 435352, 5303879, 435 29, 4241391

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO 1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20110182883, Jul 28, 2011

Filed:

Mar 3, 2011

Appl. No.:

13/040049

Inventors:

Katherin E. Combs - Spring TX, US
Frederic de Sauvage - Foster City CA, US
Liangfen Fan - Spring TX, US
Ellen Filvaroff - San Francisco CA, US
Allison Anne Byers Horner - Dickinson TX, US
Bryan Irving - San Francisco CA, US
Jagath Reddy Junutula - Fremont CA, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca Mclain - San Antonio TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Phillips - Palo Alto CA, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Teresa Gail Townsend - Houston TX, US
Peter Vogel - The Woodlands TX, US

International Classification:

A61K 39/395
A61P 3/00
A61P 9/00
A61P 25/00
A61P 19/00
G01N 33/00

US Classification:

4241301, 800 3

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.